Video

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the role of PD-1 expression in clear cell renal cell carcinoma (RCC).

An analysis looked at about 68 patients with clear cell RCC with flow cytometry and coordinated that with survival. These patients were compared with healthy non-cancer patients.

The analysis found that PD-1 expression on classical monocytes does demonstrate a poor prognosis—independent of grade, stage and other clinical variables, said Haseebuddin.

It has been shown, in the past, that PD-1 expression does decrease after surgery. The correlation that the analysis found between PD-1 expression and survival was in the preoperative setting, said Haseebuddin. If it can be determined which patients may have poor prognostic indicators, even before surgery, it is perhaps possible to identify those who would be better treated with immunotherapy.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School